To evaluate the role of FoxO3A in tumor cells subjected to metabolic stress or treated with cancer therapeutics, HCT116-FoxO3A+/+ and HCT116-FoxO3A−/− cells were cultured in LG conditions or in the presence of drugs currently administered to colorectal cancer patients and whose activity has been shown to involve FoxO3A in cellular models (metformin, cisplatin, irinotecan, 5-fluorouracil and etoposide)8,34–37. This evidence concerns the gene FOXO3 and colorectal cancer.